Patents Issued in April 18, 2019
  • Publication number: 20190111088
    Abstract: The present invention provides compositions and methods for wound healing and tissue regeneration. The compositions of the present invention comprise amniotic membrane of the placenta. In certain embodiments, the composition comprises amniotic membrane powder or solubilized amniotic membrane (SAM). In some aspects, the composition is cell-free and rich in cytokines, extracellular matrix proteins, and other components that improve tissue regeneration. In one aspect, the composition is a hydrogel scaffold that comprises amniotic membrane. The present invention reduces contraction and improves blood vessel development in regenerating tissue.
    Type: Application
    Filed: June 25, 2018
    Publication date: April 18, 2019
    Inventors: Sean V. Murphy, Aleksander Skardal, Anthony Atala
  • Publication number: 20190111089
    Abstract: The current invention is a method and system for optimally isolating adult derived stem cells from whole blood and reintroducing the adult derived stem cells into a subject at specific target areas having damaged tissue to be repaired.
    Type: Application
    Filed: December 12, 2018
    Publication date: April 18, 2019
    Applicant: Dragonfly Foundation for Research & Development
    Inventors: Mark O'Neal Speight, Henry Edward Young
  • Publication number: 20190111090
    Abstract: Bifidobacterium longum AH1362 (NCIMB 41715) produces a polysaccharide and increases energy excretion. The strain is used in the prevention or treatment of obesity and obesity-related metabolic syndrome.
    Type: Application
    Filed: December 9, 2016
    Publication date: April 18, 2019
    Inventors: Barry KIELY, Eileen Frances MURPHY, Selena HEALY
  • Publication number: 20190111091
    Abstract: The present invention is directed to a use of Lactobacillus plantarum LP10 for reducing body fat, controlling obesity or overweight, and alleviating an obesity-related disease caused by excessively high body fat. The Lactobacillus plantarum LP10 is deposited in China General Microbiological Culture Collection Center (CGMCC), the accession number is CGMCC 13008.
    Type: Application
    Filed: December 12, 2018
    Publication date: April 18, 2019
    Inventors: Chi-Chang Huang, Wen-Ching Huang, Jin-Sheng Lin, Mon-Chien Lee, Ker-Sin Ng
  • Publication number: 20190111092
    Abstract: The present disclosure provides viral microparticles comprising genetically-engineered baculoviruses (at least partially) embedded in a polymeric matrix for the local delivery of therapeutic nucleic acid molecules to the cells of a vertebrate individual (optionally in combination with a medical implant such as vascular stent platform). The viral microparticles are especially useful for promoting the healing of a wound as well as the repair of a blood vessel and prevent pathological scarring. Also provided herein are processes for making the viral microparticles, pharmaceutical compositions comprising viral microparticles as well as supports comprising the viral microparticles for the locating the viral microparticles in a wound or in the vicinity of a wound.
    Type: Application
    Filed: August 20, 2018
    Publication date: April 18, 2019
    Inventors: Satya PRAKASH, Arghya PAUL, Dominique SHUM-TIM
  • Publication number: 20190111093
    Abstract: Disclosed is a topical composition including essential combination of synergistically acting phyto-active materials, non-psychotropic phytocannabinoids from the plant of Cannabis sativa: Cannabidiol, Cannabidiolic acid, Cannabivarin Cannabigerol in combination with extract of Calendula flower and the formulation of the base to ensure the features of anti-inflammation, anti-oxidation, emollient, and bactericidal components. The topical composition is an emollient dedicated for reduction of skin lesions caused by atopic dermatitis, urticaria, radiotherapy and UV induced skin damage and acne. In addition the topical composition could reduce secretion of fats, facilitate deep skin hydration, reduce pores and exert soothing effect.
    Type: Application
    Filed: April 4, 2017
    Publication date: April 18, 2019
    Inventors: Juozas SIURKUS, Rimantas PECIURA
  • Publication number: 20190111094
    Abstract: Herbal composition for treatment and management of Thyroid dysfunction and method of preparation are disclosed herein. The disclosed composition including herbs and bhasmas may be used to treat Thyroid dysfunction and associated complications such as Hashimoto's thyroiditis, hyperthyroidism, hypothyroidism, Goiter, Thyrotoxicosis, Graves' disease, autoimmune thyroiditis etc. The method disclosed herein may be used as the main line of treatment or as supportive medication.
    Type: Application
    Filed: December 21, 2018
    Publication date: April 18, 2019
    Applicant: Muniyal Ayurvedic Research Centre
    Inventor: M Vijayabhanu Shetty
  • Publication number: 20190111095
    Abstract: The present invention provides personal care compositions comprising a carrier and a mixture of essential oil components having specific levels of eucalyptol, terpene materials and auxiliary fragrance materials. The compositions herein gentle to skin and have a fragrance and activity similar if the composition were made using the pure extracted essential oil.
    Type: Application
    Filed: December 13, 2018
    Publication date: April 18, 2019
    Inventor: Christine Marie Cahen
  • Publication number: 20190111096
    Abstract: A method for at least one of inhibiting obesity, preventing metabolic syndrome associated with obesity, treating neurodegenerative disease, preventing neurodegenerative disease, treating cardiovascular disease, preventing cardiovascular disease, treating type 2 diabetes, preventing type 2 diabetes, ameliorating sleep disturbance, regulating sleep, helping fall asleep, inhibiting inflammation, treating cancer and preventing cancer is provided, wherein the method comprises administering to a subject in need an effective amount of Mentha essential oil. A method for helping reduce the production of free radical is also provided, wherein the method comprises administering to a subject in need an effective amount of Mentha essential oil.
    Type: Application
    Filed: October 12, 2018
    Publication date: April 18, 2019
    Inventor: Yung-Hsiang LIN
  • Publication number: 20190111097
    Abstract: A method for at least one of inhibiting growth of myeloma cells, inhibiting myeloma cell-induced activation or formation of osteoclasts, and inhibiting inflammation is provided, wherein the method comprises administering to a subject in need an effective amount of grapefruit essential oil.
    Type: Application
    Filed: October 12, 2018
    Publication date: April 18, 2019
    Inventor: Yung-Hsiang LIN
  • Publication number: 20190111098
    Abstract: The present disclosure relates to health care products, disclosing a powder formulation made from inulin, ARILLUS DIMOCARPUS LONGAN, FRUCTUS ZIZIPHUS JUJUBE, FRUCTUS LYCIUM BARBARUM, RADIX REHMANNIA GLUTINOSA PRAEPARATA, SEMEN JUGLANS REGIA, HERBA CISTANCHE TUBULOSA, taurine, FRUCTUS SCHISANDRA CHINENSIS and CORTEX CINNAMOMUM CASSIA, and a simple method for preparing the powder which is suitable for large-scale production. The powder of the present disclosure promotes the growth of experimental animals, enhances the sperm motility of the animals, improves the duration and frequency of sexual response, and increases the level of sex hormones and sexual organ coefficient ratio. The powder has an obvious function of improving sexual capacity, therefore can be used to prepare the health care foods having function on improving sexual capacity.
    Type: Application
    Filed: July 1, 2018
    Publication date: April 18, 2019
    Applicant: INFINITUS (CHINA) COMPANY LTD.
    Inventors: Fang LV, Hongwei ZHAO, Qingtao TANG
  • Publication number: 20190111099
    Abstract: Embodiments described herein provide for uses of grape products, such as Chardonnay grape products and grape seed flour, for use in promoting a healthy liver, promoting healthy fat content in a liver, for treating or preventing NAFLD, and other embodiments and uses as described herein.
    Type: Application
    Filed: October 15, 2018
    Publication date: April 18, 2019
    Inventors: Torey James Arvik, Hyunsook Kim, Wallace H. Yokoyama, Scott R. Forsberg
  • Publication number: 20190111100
    Abstract: A method for at least one of stimulating natural killer cells (NK cells), enhancing effects of T helper 1 cells (Th1 cells), and inhibiting differentiation of CD4+ T cell-dependent macrophages is provided, wherein the method comprises administering to a subject in need an effective amount of convallaria essential oil.
    Type: Application
    Filed: October 12, 2018
    Publication date: April 18, 2019
    Inventor: Yung-Hsiang LIN
  • Publication number: 20190111101
    Abstract: A method for anti-aging, promoting metabolism, and/or assisting in reducing production of free radicals is provided, wherein the method comprises administering to a subject in need an effective amount of shell-flower essential oil. A method for at least one of preventing cancer, treating cancer, and inhibiting degenerative disease caused by mitochondrial aging is also provided, wherein the method comprises administering to a subject in need an effective amount of shell-flower essential oil.
    Type: Application
    Filed: October 12, 2018
    Publication date: April 18, 2019
    Inventor: Yung-Hsiang LIN
  • Publication number: 20190111102
    Abstract: An oral delivery system for collagen peptides is described, suitable for administration to both human and non-human animals, characterized in that it comprise a frozen dessert and a collagen peptide, the total amount of collagen peptide in the delivery system being less than or equal to 20% by weight of the delivery system. A process for preparing the above oral delivery system is also described.
    Type: Application
    Filed: November 5, 2017
    Publication date: April 18, 2019
    Inventor: Anatoly Derin
  • Publication number: 20190111103
    Abstract: A peptide or a salt thereof having an amino acid sequence represented by (a) or (b) shown below having a promotive effect on a proliferation of fibroblast cells, a composition for enhancing proliferation of fibroblast cells containing one or more of them, a composition for enhancing elastin production in fibroblast cells containing one or more peptides or salts thereof having an amino acid sequence represented by (a), (b) or (c) shown below and a composition for enhancing elastin production in chondrocytes containing one or more peptides or salts thereof having an amino acid sequence represented by (c) shown below.
    Type: Application
    Filed: October 9, 2018
    Publication date: April 18, 2019
    Applicants: Hayashikane Sangyo Co., Ltd., Kagoshima University
    Inventors: Eri Shiratsuchi, Kenji Miyanari, Kazunari Arima, Taihei Yamaguchi, Takahito Komine, Mizuki Takuno
  • Publication number: 20190111104
    Abstract: The purpose of the present invention is to provide a peptide which has a neuroprotective action, a neuroprotective drug and neuropathic treatment containing said peptide, and a preventive or alleviative pharmaceutical composition. This is based on the finding that a peptide fragment isolated from proline-rich protein 4 (PRP4) has a neuroprotective action.
    Type: Application
    Filed: March 30, 2017
    Publication date: April 18, 2019
    Applicant: SENJU PHARMACEUTICAL CO., LTD.
    Inventors: Takeshi NAKAJIMA, Mamiko MACHIDA, Yujiro HAYASHI
  • Publication number: 20190111105
    Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as insulin resistance.
    Type: Application
    Filed: December 19, 2018
    Publication date: April 18, 2019
    Applicants: Ipsen Pharma S.A.S., Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Heather A. HALEM, Michael DeWitt CULLER, Andrew A. BUTLER
  • Publication number: 20190111106
    Abstract: Provided are compositions that include an effective amount of a peptide or polypeptide derived from a Bordetella ACT AC domain, optionally wherein the peptide or polypeptide is 80-100% identical to an amino acid sequence as set forth in SEQ ID NOs: 1-5 and 44-53. Also provided are methods of using the same for preventing and/or treating a diseases, disorders, and conditions associated with the presence and/or development of biofilm; and for reducing the incidence of nosocomial infections; for inhibiting biofilm development and/or for reducing or eliminating biofilm present on medical, dental, and industrial surfaces.
    Type: Application
    Filed: April 4, 2017
    Publication date: April 18, 2019
    Inventors: Erik L. Hewlett, Casandra L. Hoffman, Ph.D.
  • Publication number: 20190111107
    Abstract: The present invention relates to methods for modulating the intestinal microbiota by administering one or more defensins and/or GLP-1/GLP-1 analogs and methods for prevention or treatment of gut inflammation by oral administration of one or more defensins. GLP-1 analogs such as Liraglutide, as well as mammalian and poultry alfa and beta defensins can cause a change in the composition of the microbiota and metabolome in the intestine and can therefore be used to treat or prevent gut inflammation, colorectal cancer, metabolic syndrome, obesity, prediabetes and diabetes or as lean growth promoters in the meat production.
    Type: Application
    Filed: January 26, 2017
    Publication date: April 18, 2019
    Inventors: Peter Nordkild, Jan Wehkamp, Soren Kjaerulff
  • Publication number: 20190111108
    Abstract: Provided are a pharmaceutical composition for regenerating skin, a pharmaceutical composition for improving wrinkles, a pharmaceutical composition for treating wounds, a quasi-drug composition for regenerating skin, a quasi-drug composition for improving wrinkles, a quasi-drug composition for treating wounds, a cosmetic composition for regenerating skin, a cosmetic composition for improving wrinkles, a cosmetic composition for improving wounds, and a medium composition for culturing fibroblasts, each composition including GDF11 or a human-derived adult stem cell culture medium including the same, a method of culturing fibroblasts by using the medium composition, and a method of preparing GDF11 by culturing stem cells.
    Type: Application
    Filed: December 2, 2016
    Publication date: April 18, 2019
    Inventors: Yoon Jin Kim, Seung Hee Lee, Kwang Won Seo, Kyung Sun Kang
  • Publication number: 20190111109
    Abstract: The present invention relates to compositions and methods for the delivery of agents to a subject, particularly to the central nervous system (CNS).
    Type: Application
    Filed: February 1, 2017
    Publication date: April 18, 2019
    Inventors: Alexander V. Kabanov, Yuhang Jiang, Xing Yi
  • Publication number: 20190111110
    Abstract: Methods of treating a hepatitis delta virus (HDV) infection in a human patient are provided. In some embodiments, the method comprising administering to the patient a therapeutically effective amount of interferon lambda for at least four weeks.
    Type: Application
    Filed: February 17, 2017
    Publication date: April 18, 2019
    Inventor: Eduardo Bruno Martins
  • Publication number: 20190111111
    Abstract: Pharmaceutical compositions, and methods of use thereof, for treating cerebral cavernous malformations and symptoms associated therewith. The pharmaceutical compositions include a therapeutically effective amount of a thrombospondin 1 protein agent. A thrombospondin 1 protein agent can include thrombospondin 1 protein, a functional fragment of thrombospondin 1 protein, an isomer, a homolog, or a peptidomimetic of thrombospondin 1 protein or a functional fragment thereof. The pharmaceutical compositions and methods can further comprise a Rho Kinase inhibitor.
    Type: Application
    Filed: April 13, 2017
    Publication date: April 18, 2019
    Inventors: Mark H. Ginsberg, Miguel Alejandro Lopez-Ramirez
  • Publication number: 20190111112
    Abstract: Disclosed is a novel peptide capable of preventing or treating ocular surface disease by inhibiting or improving pathological changes caused by neovascularization, opacification, fibrosis and inflammation of the cornea, the peptide having an amino acid sequence represented by SEQ ID NO: 1 and more particularly, provides a collagen type II ?1-based peptide isolated from an animal chondrocyte cell-derived extracellular matrix and use thereof.
    Type: Application
    Filed: February 9, 2017
    Publication date: April 18, 2019
    Applicant: EYEBIO KOREA
    Inventor: Jae Wook YANG
  • Publication number: 20190111113
    Abstract: Compositions and methods using an engineered cardiac fibroblast-derived 3-dimensional extracellular matrix (ECM) are disclosed. The ECM includes the structural proteins fibronectin, collagen type I, collagen type III, and elastin, and from 60% to 90% of the structural proteins present in the engineered extracellular matrix are fibronectin. The compositions, which can be used to treat cardiac disease or ischemic disease or injury, are injectable compositions, where the ECM is diced into small fragments or lyophilized into a powder. The disclosed methods include a method of treating ischemic disease or injury by contacting a cell free patch made from the ECM with the injured tissue, without the concomitant delivery of therapeutic cells, and a method of treating ischemic limb injury by contacting a patch, either by itself or seeded with therapeutic cells, with the injured limb tissue.
    Type: Application
    Filed: November 21, 2018
    Publication date: April 18, 2019
    Inventors: Eric Schmuck, Amish Raval
  • Publication number: 20190111114
    Abstract: The invention relates to method of treating or inhibiting progression of hemoglobinopathy in a subject in need thereof comprising inhibiting interaction between LRF-BTB and CHD protein-LBD.
    Type: Application
    Filed: December 29, 2016
    Publication date: April 18, 2019
    Inventor: Takahiro Maeda
  • Publication number: 20190111115
    Abstract: Compositions of recombinant intravenous immunoglobulin (rIVIG) proteins and methods for purification and use of rIVIG proteins. The compositions comprise oligomeric Fc molecules which bind to Fc receptors with high avidity. The rIVIG proteins are useful as immunomodulatory molecules for the treatment of immune disorders including autoimmune diseases, such as refractory immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy, multiple sclerosis, lupus, Graves Disease, Kawasaki disease, dermatomyositis, myasthenia gravis, Guillain-Barre syndrome, autoimmune hemolytic anemia, and other immune and inflammatory conditions. The rIVIG proteins can also be used as immunomodulators in patients to reduce the immune rejection of organ transplants, stem cell transplants and bone marrow transplantation.
    Type: Application
    Filed: March 29, 2017
    Publication date: April 18, 2019
    Inventors: Yen-Ming Hsu, Jeng-Shin Lee, Hsiu-Ching Chang
  • Publication number: 20190111116
    Abstract: A vector have an expression cassette containing have a hIDUA gene has a sequence of SEQ ID NO: 1 (FIG. 1) or a sequence at least about 95% identical thereto which encodes a functional human alpha-L-iduronidase is provided. The vector may be a production vector or a rAAV8. Also provided are compositions containing these vectors and methods of treating MPSI and the symptoms associated with Hurler, Hurler-Scheie and Scheie syndromes.
    Type: Application
    Filed: October 22, 2018
    Publication date: April 18, 2019
    Inventors: James M. Wilson, Brittney L. Gurda
  • Publication number: 20190111117
    Abstract: Provided are compositions and methods for prophylaxis and/or therapy of ErbB2-positive cancer. The compositions include pharmaceutical preparations that contain isolated or recombinant or modified peptidase D (PEPD) proteins. The methods include prophylaxis and/or therapy of ErbB2-positive cancer by administering a PEPD to an individual who has or is at risk for developing ErbB2-positive cancer.
    Type: Application
    Filed: December 17, 2018
    Publication date: April 18, 2019
    Inventors: Yuesheng ZHANG, Lu YANG, Yun LI
  • Publication number: 20190111118
    Abstract: The invention relates to chemically as well as physically stable compositions comprising Factor VII or a Factor VII-related polypeptide such that these compositions can be stored, handled and used at room temperature.
    Type: Application
    Filed: October 18, 2018
    Publication date: April 18, 2019
    Inventors: Michael Bech Jensen, Birthe Lykkegaard Hansen, Troels Kornfelt
  • Publication number: 20190111119
    Abstract: The present invention relates to microstructure formulation techniques for botulinum toxin. The microstructure formulation techniques for botulinum toxin according to the present invention make it possible to precisely control the concentration of botulinum toxin and to alleviate the pain occurring when botulinum toxin is administered into the human body, and also enable botulinum toxin to be accurately administered to a desired position. Thus, the present invention is expected to greatly contribute to the safe and convenient medical use of botulinum toxin.
    Type: Application
    Filed: October 12, 2017
    Publication date: April 18, 2019
    Inventors: Kyeong Yeop Moon, Chang Jin Lee, Dae Gun Kim, Dong Hoon Oh, Do Hyun Kang, Woo Ran Lee, Jeong Gyu Lee, Jun Jin Yoon
  • Publication number: 20190111120
    Abstract: The present invention provides a method for detecting cancer using a protein expressed in various cancers, and a pharmaceutical composition for the treatment or prevention of such cancer using the protein as an indicator. Furthermore, the present invention provides a pharmaceutical composition containing a cancer antigen peptide derived from the protein. More particularly, the method comprises the step of determining the presence or amount of an eEF2 polypeptide or an eEF2 antibody in a sample obtained from a subject.
    Type: Application
    Filed: December 13, 2018
    Publication date: April 18, 2019
    Applicant: International Institute of Cancer Immunology, Inc.
    Inventors: Haruo SUGIYAMA, Yusuke OJI
  • Publication number: 20190111121
    Abstract: The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR) E. coli strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.
    Type: Application
    Filed: December 21, 2018
    Publication date: April 18, 2019
    Applicant: ARSANIS BIOSCIENCES GMBH
    Inventors: Eszter NAGY, Gábor NAGY, Valéria SZIJÁRTO, Zoltán MAGYARICS, Irina MIRKINA, Luis GUACHALLA, Adriana BADARAU, Gerhild ZAUNER, Jolanta LUKASIEWICZ
  • Publication number: 20190111122
    Abstract: The present disclosure relates to methods for exporting target proteins (e.g., surface lipoproteins) from the cytosol to the extracellular surface of bacterial cells using surface lipoprotein assembly modulator (SLAM) polypeptides. The use of SLAM polypeptides in a method of preparing vaccines useful in the prevention of bacterial infectious diseases is also taught.
    Type: Application
    Filed: February 10, 2017
    Publication date: April 18, 2019
    Inventors: Trevor F. Moraes, Christine Chieh-Lin Lai, Yogesh Hooda, Andrew Judd, Anthony B. Schryvers, Scott D. Gray-Owen
  • Publication number: 20190111123
    Abstract: Protein complex variants, compositions, and methods of use thereof are provided. The protein complex variant includes a cholera toxin B subunit variant having one or more modifications thereto. The method of use thereof includes treating a disease by administering an effective amount of a composition including a cholera toxin B subunit variant to a subject in need thereof.
    Type: Application
    Filed: June 29, 2016
    Publication date: April 18, 2019
    Applicant: University of Louisville Research Foundation, Inc.
    Inventors: Nobuyuki MATOBA, Keegan BALDAUF, Joshua ROYAL
  • Publication number: 20190111124
    Abstract: Embodiments herein relate to compositions and methods for stabilizing live alphaviruses. Other embodiments relate to compositions and methods for reducing degradation of live, attenuated alphaviruses. Certain embodiments relate to providing a stabilizing composition while reducing immune reaction in a subject to excipients that stabilize the live alphaviruses by providing improved formulations. Yet other embodiments relate to uses of compositions disclosed herein in kits for portable applications and methods wherein the compositions reduce degradation of the live alphaviruses.
    Type: Application
    Filed: March 27, 2017
    Publication date: April 18, 2019
    Applicant: Takeda Vaccines, Inc.
    Inventors: Jill Ann Livengood, Timothy Duane Powell
  • Publication number: 20190111125
    Abstract: The invention relates to the use of a bacterial artificial chromosome (BAC) for the preparation of a vaccine, wherein the BAC comprises an inducible bacterial ori sequence for amplification of the BAC to more than 10 copies per bacterial cell. Plus a viral expression cassette comprising a cDNA of an attenuated RNA virus genome and comprising cis-regulatory elements for transcription of said viral cDNA in mammalian cells and for processing of the transcribed RNA into infectious viral RNA.
    Type: Application
    Filed: September 17, 2018
    Publication date: April 18, 2019
    Inventors: Kai DALLMEIER, Johan NEYTS
  • Publication number: 20190111126
    Abstract: The present invention provides co-administration (e.g., immunogenic cocktail and/or prime-boost regimens) of computationally optimized H5N1 influenza hemagglutinin (HA) polypeptides that. Co-administration of the optimized H5N1 influenza hemagglutinin (HA) polypeptides facilitates synergistic neutralization of viral infection and provides for improved protective immunity (e.g., a broad reactive immune response) to multiple H5N1 influenza virus clades and strains.
    Type: Application
    Filed: December 18, 2015
    Publication date: April 18, 2019
    Inventors: Ted Milburn Ross, Tim Alefantis, Donald Martin Carter, Christopher Austin Darby, Harold Kleanthous
  • Publication number: 20190111127
    Abstract: Recombinant herpes simplex virus 2 (HSV-2) vaccine vectors, virions thereof, compositions and vaccines comprising such, and methods of use thereof are each provided.
    Type: Application
    Filed: June 1, 2018
    Publication date: April 18, 2019
    Applicant: ALBERT EINSTEIN COLLGE OF MEDICINE, INC.
    Inventors: William Jacobs, JR., Pablo A. Gonzalez-Munoz, Betsy Herold, Christopher Petro
  • Publication number: 20190111128
    Abstract: A method for preserving a polypeptide comprising: (a) providing an aqueous solution of (i) the polypeptide, (ii) one or more sugars, and (iii) a compound of formula (I) or a physiologically acceptable salt or ester thereof and/or a compound of formula (II) or a physiologically acceptable salt or ester thereof; and (b) drying the solution to form a composition incorporating the polypeptide.
    Type: Application
    Filed: June 20, 2018
    Publication date: April 18, 2019
    Inventors: Jeffrey DREW, David Thomas WOODWARD, Stephen WARD
  • Publication number: 20190111129
    Abstract: Provided is a stable pharmaceutical composition comprising an anti-human TSLP receptor antibody, capable of inhibiting the generation of chemically modified substances, such as deamidated forms and oxidized forms, or degradants, or multimers. The pharmaceutical composition comprises an anti-human TSLP receptor antibody, a pharmaceutically acceptable buffer, arginine or a pharmaceutically acceptable salt thereof, and a surfactant.
    Type: Application
    Filed: December 16, 2016
    Publication date: April 18, 2019
    Applicant: ASTELLAS PHARMA INC.
    Inventors: Megumi IKEDA, Akinori CHIKUSHI
  • Publication number: 20190111130
    Abstract: Disclosed herein are compositions comprising a pharmaceutical agent and an ultrasound enhancing agent. The compositions are useful in combination with ultrasound to enhance delivery of a pharmaceutical agent to, for example, tissue of a subject in need thereof. Accordingly, also provided herein are methods involving ultrasound for delivering a pharmaceutical agent to a subject, e.g., a subject that has inflammatory bowel disease or proctitis.
    Type: Application
    Filed: October 16, 2018
    Publication date: April 18, 2019
    Inventors: Robert S. Langer, Carlo Giovanni Traverso, Dan Minahan, Taylor A. Bensel, Thomas von Erlach, Carl Magnus Schoellhammer
  • Publication number: 20190111131
    Abstract: The present invention relates to an apparatus for inhibiting oncogene-induced malignant carcinogenesis, including an irradiation unit for applying low-dose radiation to a subject, and to a method of inhibiting oncogene-induced malignant carcinogenesis, including applying low-dose radiation to a subject, whereby oncogene-induced malignant carcinogenesis can be inhibited by means of the apparatus and method of the present invention.
    Type: Application
    Filed: August 23, 2016
    Publication date: April 18, 2019
    Inventors: Seonyoung NAM, Kwang Hee YANG, Su-Jae LEE, Rae-Kwon KIM
  • Publication number: 20190111132
    Abstract: A novel 34 amino acid long collagen-like peptide rich in proline, hydroxyproline, and glycine, and with several photoreactive N-acyl-7-nitroindoline units incorporated into the peptide backbone was synthesized by on-resin fragment condensation. The circular dichroism measurement of this peptide supports a stable triple helix structure. This peptide has potential as a new biomimetic material with built-in latent photochemical functions that enable the decomposition into small peptide fragments by illumination with UV light of 350 nm. Using a photoreactive glycine derivative as a model compound for the collagen-like peptide, we demonstrate that its photolysis can also be triggered by a two-photon absorption process using a femtosecond laser at 710 nm. When a thin film of this compound is irradiated with femtosecond laser light at 710 nm the photochemistry occurs only at locations of irradiation.
    Type: Application
    Filed: October 18, 2018
    Publication date: April 18, 2019
    Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Chunqiang Li, Thomas Boland, Hector P. Del Castillo, Katja Michael, Binata Joddar, Alfredo Ornelas
  • Publication number: 20190111133
    Abstract: A system for delivering a therapeutic agent to cell or tissue of a subject includes a mesoporous silica iron oxide nanoparticle with one or more therapeutic agents that are contained in a mesoporous silica layer of the nanoparticle and a remote radiofrequency (RF) energy source for applying RF energy to the nanoparticle effective to release the one or more therapeutic agents from the nanoparticle by mechanical tumbling and/or vibration of the nanoparticle, wherein release of the one or more therapeutic agents not caused by a hyperthermic response of the nanoparticle to the RF energy.
    Type: Application
    Filed: October 17, 2018
    Publication date: April 18, 2019
    Inventors: Efstathios Karathanasis, Prabhani Atukorale, Wyatt Becicka, Pete Bielecki
  • Publication number: 20190111134
    Abstract: Methods and systems for radiation therapy involve administering a payload/combination of biocompatible high-Z and semiconductor NPs to tissue, such as a tumor or an eye. Ionizing radiation may be directed towards the payload, and ionized electrons generate Cerenkov radiation (CR). The CR interacts with semiconductor NPs to produce chemical species that are damaging to cells. The payload may be administered via injection or via a radiotherapy (RT) device that includes NPs in a biodegradable polymer matrix. Biodegradation of the polymer matrix, which results in release of its payload, may be remotely activated using, for example, electromagnetic or sound waves. The payload may include one or more immunologic adjuvants capable of promoting an immunologic response at remote sites (such as a metastatic tumors) that are separate from the site at which the NPs and adjuvants were administered.
    Type: Application
    Filed: April 3, 2017
    Publication date: April 18, 2019
    Inventor: Wilfred F. Ngwa
  • Publication number: 20190111135
    Abstract: Optogenetic and chemogenetic actuators are critical for deconstructing the neural correlates of behavior. However, these tools have several drawbacks, including invasive modes of stimulation or slow on/off kinetics. These disadvantages have been overcome by synthesizing a magnetically sensitive actuator, Magneto, comprised of the cation channel, TRPV4, fused to the paramagnetic protein, ferritin. Magneto permits non-invasive magnetic control over neuronal activity by showing remote stimulation of cells using in vitro calcium imaging assays, electrophysiological recordings in brain slices, in vivo electrophysiological recordings in freely moving mice, and behavioral outputs in zebrafish and mice. As proof of concept, the first magnetogenetic control of the nervous system was demonstrated by using Magneto to delineate a causal role of striatal dopamine receptor 1 neurons in mediating reward behavior in mice.
    Type: Application
    Filed: October 21, 2016
    Publication date: April 18, 2019
    Inventors: Ali Deniz Guler, Michael Alex Wheeler
  • Publication number: 20190111136
    Abstract: This invention provides methods and systems for achieving high-specificity killing of targeted cells using Magneto-Electric Nano-Particles (MENPs) and functional or diagnostic imaging that detects changes at the cellular level. Embodiments comprise injecting into a patient's body manufactured MENPs that have a higher tendency to accumulate near or attach to targeted cells through one or more physical forces and/or biological mechanisms; and applying a magnetic field to the MENPs to generate an action that is sufficient to cause death of the targeted cells, and using an imaging apparatus to image or detect a specific property of the MENPs or changes in a property of the MENPs due to the coupling of the MENPs with their surrounding environment.
    Type: Application
    Filed: December 12, 2018
    Publication date: April 18, 2019
    Applicant: RF DSP Inc.
    Inventor: Ping Liang
  • Publication number: 20190111137
    Abstract: The present invention is directed to a combination of therapeutic compounds and treatment methods and kits using the combination. In particular, one of the combination affects the NCCa-ATP channel of neural tissue, including neurons, glia and blood vessels within the nervous system. Exemplary SUR1 and/or TRPM4 antagonists that inhibit the NCCa-ATP channel may be employed in the combination. The combination therapy also employs one or more of a non-selective cation channel blocker and/or an antagonist of VEFG, NOS, MMP, or thrombin. Exemplary indications for the combination therapy includes the prevention, diminution, and/or treatment of injured or diseased neural tissue, including astrocytes, neurons and capillary endothelial cells, that is due to ischemia, tissue trauma, brain swelling and increased tissue pressure, or other forms of brain or spinal cord disease or injury, for example.
    Type: Application
    Filed: May 8, 2018
    Publication date: April 18, 2019
    Inventors: J. Marc Simard, Vladimir Gerzanich